Table 7.
Relative risks, attributable fractions in the exposed and population-attributable risks for high- vs. low-cannabis-exposure nations, respectively.
| Cancer | p-Value | RR (C.I.) | AFE (C.I.) | PAF (C.I.) |
|---|---|---|---|---|
| Kaposi | 1.86 × 10−170 | 2.081 (1.9739, 2.1939) | 0.5195 (0.4934, 0.5442) | 0.2573 (0.2376, 0.2765) |
| Liver | 0.0000 | 1.7627 (1.7556, 1.7698) | 0.4327 (0.4304, 0.435) | 0.4077 (0.4055, 0.4099) |
| Thyroid | 0.0000 | 1.6921 (1.6861, 1.6981) | 0.409 (0.4069, 0.4111) | 0.385 (0.383, 0.3871) |
| Stomach | 0.0000 | 1.6847 (1.68, 1.6893) | 0.4064 (0.4048, 0.408) | 0.3827 (0.3811, 0.3843) |
| Oropharynx_Broad | 0.0000 | 1.6204 (1.6104, 1.6304) | 0.3829 (0.3791, 0.3866) | 0.3306 (0.3271, 0.3342) |
| Larynx | 0.0000 | 1.5906 (1.5822, 1.5991) | 0.3713 (0.368, 0.3746) | 0.3524 (0.3492, 0.3557) |
| Breast | 0.0000 | 1.4899 (1.4882, 1.4915) | 0.3288 (0.3281, 0.3296) | 0.3095 (0.3088, 0.3102) |
| All Cancers | 0.0000 | 1.4057 (1.4047, 1.4067) | 0.2886 (0.2881, 0.2891) | 0.2411 (0.2406, 0.2415) |
| Hodgkin’s | 0.0000 | 1.2985 (1.2918, 1.3054) | 0.2299 (0.2259, 0.2339) | 0.213 (0.2092, 0.2168) |
| Bladder | 0.0000 | 1.2896 (1.2866, 1.2925) | 0.2246 (0.2228, 0.2263) | 0.2077 (0.206, 0.2094) |
| Kidney | 0.0000 | 1.287 (1.2836, 1.2903) | 0.223 (0.221, 0.225) | 0.2062 (0.2043, 0.2081) |
| Pancreas | 0.0000 | 1.2859 (1.2822, 1.2895) | 0.2223 (0.2201, 0.2245) | 0.2056 (0.2035, 0.2077) |
| Prostate | 0.0000 | 1.274 (1.2728, 1.2751) | 0.2151 (0.2144, 0.2158) | 0.1984 (0.1978, 0.1991) |
| Lung | 0.0000 | 1.2704 (1.2685, 1.2724) | 0.2129 (0.2116, 0.2141) | 0.1992 (0.198, 0.2004) |
| Leukaemia | 0.0000 | 1.2471 (1.2436, 1.2507) | 0.1981 (0.1959, 0.2004) | 0.1819 (0.1798, 0.1841) |
| Colorectum | 0.0000 | 1.2186 (1.2173, 1.22) | 0.1794 (0.1785, 0.1803) | 0.1646 (0.1638, 0.1655) |
| All Cancers nNMSC | 0.0000 | 1.2121 (1.2115, 1.2127) | 0.175 (0.1746, 0.1754) | 0.1607 (0.1603, 0.1611) |
| Gallbladder and Biliary | 1.91 × 10−252 | 1.109 (1.1023, 1.1156) | 0.0982 (0.0928, 0.1036) | 0.0905 (0.0855, 0.0955) |
| Myeloma | 0.0000 | 1.1072 (1.1022, 1.1123) | 0.0968 (0.0927, 0.101) | 0.0884 (0.0846, 0.0922) |
| Leukaemia—Myeloid | 6.17 × 10−64 | 1.0916 (1.0806, 1.1028) | 0.084 (0.0746, 0.0933) | 0.0655 (0.0581, 0.073) |
| Leukaemia—Lymphoid | 9.73 × 10−101 | 1.0805 (1.0728, 1.0883) | 0.0745 (0.0679, 0.0811) | 0.0582 (0.0529, 0.0634) |
| Corpus Uteri | 0.0000 | 1.0657 (1.0638, 1.0676) | 0.0616 (0.06, 0.0633) | 0.0543 (0.0528, 0.0557) |
| Cervix | 0.0000 | 1.056 (1.0534, 1.0586) | 0.053 (0.0507, 0.0554) | 0.0481 (0.046, 0.0503) |
| Testis | 1.76 × 10−119 | 1.0386 (1.0353, 1.042) | 0.0372 (0.0341, 0.0403) | 0.0337 (0.0309, 0.0365) |
| Ovary | 2.24 × 10−92 | 1.0245 (1.0222, 1.0269) | 0.024 (0.0217, 0.0262) | 0.0217 (0.0196, 0.0238) |
| Anus | 1.47 × 10−8 | 1.0254 (1.0164, 1.0346) | 0.0248 (0.0161, 0.0334) | 0.0225 (0.0146, 0.0303) |
| Non-Hodgkin’s Lymphoma | 1.19 × 10−70 | 0.9781 (0.9757, 0.9805) | −0.0224 (−0.0249, −0.0199) | −0.02 (−0.0223, −0.0178) |
| Melanoma | 6.32 × 10−297 | 0.9571 (0.9549, 0.9594) | −0.0448 (−0.0472, −0.0424) | −0.0403 (−0.0425, −0.0381) |
| Hepatocellular | 0.0175 | 0.9143 (0.8412, 0.9938) | −0.0937 (−0.1888, −0.0063) | −0.0848 (−0.1699, −0.006) |
| Oesophagus | 0.0000 | 0.8962 (0.8929, 0.8996) | −0.1158 (−0.12, −0.1116) | −0.1037 (−0.1074, −0.0999) |
| Brain | 0.0000 | 0.7878 (0.7855, 0.79) | −0.2694 (−0.273, −0.2658) | −0.2371 (−0.2402, −0.234) |
| Penis | 0.0000 | 0.7663 (0.7604, 0.7722) | −0.305 (−0.3152, −0.2949) | −0.2659 (−0.2745, −0.2574) |
| Vulva | 0.0000 | 0.7187 (0.7103, 0.7271) | −0.3915 (−0.4078, −0.3753) | −0.2291 (−0.2375, −0.2207) |
| Vagina | 2.72 × 10−162 | 0.7082 (0.6907, 0.7262) | −0.412 (−0.4478, −0.377) | −0.2403 (−0.2585, −0.2223) |
| Vulva and Vagina | 0.0000 | 0.6967 (0.6918, 0.7017) | −0.4353 (−0.4456, −0.4251) | −0.3788 (−0.3874, −0.3703) |
| Oropharynx | 0.0000 | 0.6292 (0.6245, 0.6339) | −0.5894 (−0.6012, −0.5776) | −0.3675 (−0.3739, −0.3612) |
Table key: R.R.—Relative risk; AFE—attributable fraction in the exposed; PAR—population-attributable risk; C.I.—confidence interval; p-value—significance level.